Recent Investment Analysts’ Ratings Changes for Apyx Medical (APYX)

Several brokerages have updated their recommendations and price targets on shares of Apyx Medical (NASDAQ: APYX) in the last few weeks:

• 12/29/2025 – Apyx Medical had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/17/2025 – Apyx Medical was upgraded by analysts at Zacks Research to a “hold” rating.
• 12/15/2025 – Apyx Medical is now covered by analysts at Roth Capital. They set a “buy” rating and a $6.00 price target on the stock.
• 12/15/2025 – Apyx Medical was upgraded by analysts at Roth Capital to a “strong-buy” rating.
• 11/22/2025 – Apyx Medical was upgraded by analysts at Wall Street Zen to a “hold” rating.
• 11/12/2025 – Apyx Medical was upgraded by analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating. They now have a $8.00 price target on the stock.

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.